P3 Research secures investment from Genesis Capital to accelerate expansion

  • P3 takes precedence new zealand Clinical trial network established in 1998

  • 7 bases nationwide new zealandP3’s clients span the globe, from large multinational corporations to small biotech companies.

  • Genesis Capital becomes major shareholder in clinical trials group alongside existing shareholders

Wellington, New Zealand, December 22, 2022 /PR Newswire/ — P3 research,reading new zealand Nationwide network of 7 clinical trial sites new zealand As an investor in Genesis Capital, a private equity firm specializing in healthcare.

P3 is either: new zealand The world’s largest clinical site network focuses on recruitment excellence, high-quality data and streamlined processes in Phase 2 and 3 trials for global pharmaceutical sponsors and CROs. With its significant network of facilities, P3 is well known among sponsors for its ability to deliver patient recruitment from diverse cross-sections of the country. It also allows New Zealanders across the country access to medicines that are otherwise difficult or expensive to find. .

The investment builds on Genesis’ backing of bioanalytical laboratory Crux Biolabs earlier in the year as part of the fund’s continued focus on its promising clinical trial services business. Thing. Australia When new zealand,

Professor Richard Stubbsthe CEO of P3 Research, said:new zealand It has become an increasingly preferred destination for the global clinical trials industry. With Genesis on board, we look forward to: Further expand our high-quality service capabilities at new sites to serve newly expanded therapeutic areas for our clients, while increasing patient access to the latest breakthrough therapies across a wide range of disease conditions.”

The contract research sector has seen accelerated growth across the region in recent years, in part due to the emphasis on community-based trials, such as those conducted at P3 clinics, to rapidly bring breakthroughs to global markets. .

In addition to expansion plans, investment from Genesys will also focus on enhancing P3’s technology and patient recruitment capabilities to further meet growing global demand from CROs and sponsors for high-quality clinical trials To do.

Michael Callistosaid a partner at Genesis Capital. “The pandemic has highlighted the critical need for this kind of organization in driving medical progress at the pace needed to make an impact on a global scale. We rely on clinical trials. new zealand And I’m excited to be a part of their next stage of growth. ”

Genesis Capital was advised by Harmos Horton Lusk on legal matters and EY on accounting.

About P3 Research


P3 research is a leading and respected independent clinical trials firm dedicated to conducting high-quality clinical research on behalf of pharmaceutical companies, contract research organizations, and individual researchers worldwide.

About Genesis Capital


genesis capital is a specialist investment firm focused on building strong healthcare businesses. Australia When new zealandThey are active partners working with management teams to unlock growth in healthcare businesses with the potential to become industry leaders.

Source P3 study

Source link

Leave a Reply

%d bloggers like this: